Prevention by dehydroepiandrosterone of the development of mammary carcinoma induced by 7,12-dimethylbenz(a)anthracene (DMBA) in the rat
- PMID: 8012037
- DOI: 10.1007/BF00665681
Prevention by dehydroepiandrosterone of the development of mammary carcinoma induced by 7,12-dimethylbenz(a)anthracene (DMBA) in the rat
Abstract
The concentration of serum dehydroepiandrosterone sulfate (DHEA-S) and DHEA decreases markedly during aging, and low circulating levels of DHEA have been associated with a higher incidence of breast cancer in women. Using 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat as model, we have studied the effect of increasing serum levels of DHEA released from Silastic implants on the incidence of these tumors in the rat. Treatment with increasing doses of DHEA leading to serum DHEA levels comparable to those observed in normal adult women (7.1 +/- 0.6 nM and 17.5 +/- 1.1 nM) caused a progressive inhibition of tumor development from 68% bearing tumors in control animals to 22% and 11%, respectively. The average tumor area per rat decreased from 2.81 cm2 in intact control animals to 0.96 and 0.09 cm2 in the groups treated with the same doses of DHEA, respectively. The present data indicate that circulating levels of DHEA similar to those found in normal adult premenopausal women exert a potent inhibitory effect on the development of DMBA-induced mammary tumors in the rat, thus suggesting the possibility of a new and more physiological approach for the prevention of breast cancer in women.
Similar articles
-
Combined effects of dehydroepiandrosterone and EM-800 on bone mass, serum lipids, and the development of dimethylbenz(A)anthracene-induced mammary carcinoma in the rat.Endocrinology. 1997 Oct;138(10):4435-44. doi: 10.1210/endo.138.10.5429. Endocrinology. 1997. PMID: 9322961
-
Effect of dehydroepiandrosterone on bone mass, serum lipids, and dimethylbenz(a)anthracene-induced mammary carcinoma in the rat.Endocrinology. 1997 Aug;138(8):3387-94. doi: 10.1210/endo.138.8.5345. Endocrinology. 1997. PMID: 9231792 Clinical Trial.
-
Opposite effects of dehydroepiandrosterone on the growth of 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas.Anticancer Res. 1992 Sep-Oct;12(5):1479-83. Anticancer Res. 1992. PMID: 1444210
-
Dietary supplements of dehydroepiandrosterone in relation to breast cancer risk.Eur J Clin Nutr. 1999 Oct;53(10):771-5. doi: 10.1038/sj.ejcn.1600889. Eur J Clin Nutr. 1999. PMID: 10556982 Review.
-
Cancer prevention with dehydroepiandrosterone and non-androgenic structural analogs.J Cell Biochem Suppl. 1995;22:210-7. doi: 10.1002/jcb.240590826. J Cell Biochem Suppl. 1995. PMID: 8538200 Review.
Cited by
-
Androgen Receptor: A Complex Therapeutic Target for Breast Cancer.Cancers (Basel). 2016 Dec 2;8(12):108. doi: 10.3390/cancers8120108. Cancers (Basel). 2016. PMID: 27918430 Free PMC article. Review.
-
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer.Oncologist. 2019 Jun;24(6):743-e205. doi: 10.1634/theoncologist.2018-0243. Epub 2018 Dec 27. Oncologist. 2019. PMID: 30591548 Free PMC article. Clinical Trial.
-
The role of androgens in experimental rodent mammary carcinogenesis.Breast Cancer Res. 2014 Nov 25;16(6):483. doi: 10.1186/s13058-014-0483-x. Breast Cancer Res. 2014. PMID: 25928046 Free PMC article. Review.
-
Dehydroepiandrosterone inhibits the progression phase of mammary carcinogenesis by inducing cellular senescence via a p16-dependent but p53-independent mechanism.Breast Cancer Res. 2005;7(6):R1132-40. doi: 10.1186/bcr1350. Epub 2005 Nov 16. Breast Cancer Res. 2005. PMID: 16457693 Free PMC article.
-
DHEA as physiological replacement therapy at menopause.J Endocrinol Invest. 1998 Jun;21(6):399-401. doi: 10.1007/BF03350777. J Endocrinol Invest. 1998. PMID: 9699133 Review. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical